Archive · 28 Nov 2025
HIV Drug Lenacapavir Delayed in India
There's a new HIV drug called Lenacapavir that's really important because it can help prevent HIV and might even help end AIDS.
The drug company Gilead Sciences gave permission to some Indian companies to make cheaper versions of this drug.
But even though these cheaper versions could be made, there are delays because of rules and patents.
People who work on treating HIV are worried because these delays mean the drug won't be available soon in India or other countries that need it.
They think the rules should be changed so the drug can be made and sold faster, especially in places like South Africa where many new HIV cases happen.
Without these cheaper versions, it will be harder for people to get the medicine they need.
Lenacapavir, a breakthrough HIV drug, is facing delays in India due to regulatory and patent issues.
Gilead Sciences issued voluntary licenses to Indian generic drugmakers, but regulatory approvals are pending.
Treatment activists argue that regulatory delays and Gilead’s patent filings are hindering global access to affordable Lenacapavir.
Indian manufacturers could potentially offer Lenacapavir at US$25–40 per person per year, a significant reduction from current prices.
Delays in India's approval process could impact the availability of generic Lenacapavir in low- and middle-income countries, particularly those dependent on Indian generics.
- Who
- Gilead Sciences, Indian generic drugmakers (Dr Reddy’s Laboratories, Emcure, Hetero), treatment activists, and healthcare professionals
- What
- Delays in the availability of the HIV drug Lenacapavir in India due to regulatory and patent issues
- When
- Current situation as of November 27, 2025, with potential availability in 2026
- Where
- India, with implications for global access, particularly in low- and middle-income countries
- Why
- Regulatory delays and Gilead’s patent filings are causing delays in the approval and distribution of the generic version of Lenacapavir
- Drug Name
- Lenacapavir
- Manufacturer
- Gilead Sciences
- Generic Manufacturers
- Dr Reddy’s Laboratories, Emcure, Hetero, Eva Pharma, Ferozsons Laboratories, Mylan
- Approval Status
- Approved by USFDA, EMA, and WHO
- Potential Price
- US$25–40 per person per year
- Expected Availability
- 2026 or later
- Key Advocates
- Third World Network, Sankalp Rehabilitation Trust, Health Justice Initiative
